Endothelin A antagonist LU‐135252 and trandolapril in the treatment of the Cohen–Rosenthal diabetic hypertensive rat

C. Hofman,E. Gabai,E. Peleg,K. Munter,T. Rosenthal
DOI: https://doi.org/10.1080/08037050510008913
2005-04-01
Blood Pressure
Abstract:Background. Hypertension and non‐insulin‐dependent diabetes mellitus (NIDDM) often occur simultaneously and the combination requires vigorous control of hypertension. This can generally be achieved by a combination of antihypertensive drugs. The present study examines the antihypertensive and possible hypoglycemic effects of combined therapy with endothelin A (ETA) receptor antagonist LU‐135252 and angiotensin‐converting enzyme (ACE) inhibitor trandolapril in male Cohen–Rosenthal Diabetic Hypertensive (CRDH) rats. Methods. Rats were divided into four groups as follows: group I served as control; group II – LU‐135252 30 mg/kg/day; group III – trandolapril 0.1 mg/kg/day and group IV – both LU‐135252 30 mg/kg/day and trandolapril 0.1 mg/kg/day. Systolic blood pressure (SBP) and plasma glucose levels were evaluated at the beginning of the experiment and after 2, 4 and 6 weeks. Results. SBP decreased significantly in all treated groups after 2, 4 and 6 weeks of treatment compared to baseline. Maximum decrease was in group IV (combination) from 174.8±3.7 to 136.1±2.4 mmHg (22%) (p<0.0001); in group III (trandolapril) from 165.8±2.7 to 137.5±2.9 mmHg (17%) (p = 0.0002); and in group II (LU‐135252) and from 169.1±3.1 to 147.8±2.5 mmHg (12%) (p = 0.0004). Glucose levels in plasma decreased significantly after 6 weeks of treatment. Maximum decrease was in group IV: from 501.0±42.8 to 178.6±7.3 mg/dl (62%) (p<0.0001); in group III from 428.2±47.7 to 146.8±5.6 mg/dl (63%) (p<0.0001); and in group II from 491.2±39.3 to 272.2±28.3 mg/dl (42%) (p = 0.0002). Conclusion. The SBP decrease was additive when both drugs were given together. Thus, combination of ETA antagonist and ACE inhibitor appears to offer a rational fixed‐dose antihypertensive therapy, which is superior to that of either drug alone. The decrease in glucose level, which was the least impressive while on LU‐135252 alone, was more prominent during combination after 2 weeks, although without further decrease.
What problem does this paper attempt to address?